the first we point mutated the mouse CII gene to express an earlier defined T-cell epitope, CII-(256-270), present in rat CII. In the second we mutated the mouse type I collagen gene to express the same T-cell epitope. The mice with mutated type I collagen showed no T-cell reactivity to rat CII and were resistant to CIA. Thus, the CII-(256-270) epitope is immunodominant and critical for development of CIA. In contrast, the mice with mutated CII had an intact B-cell response and had T cells which could produce y interferon, but not proliferate, in response to CII. They developed CIA, albeit with a reduced incidence. Thus, we conclude that T cells recognize CII derived from endogenous cartilage and are partially tolerized but may still be capable of mediating CIA. Rheumatoid arthritis (RA) is an autoimmune inflammatory disease affecting peripheral joints. The main genetic association is to the major histocompatibility complex (MHC) class II region (HLA-DR) (1, 2) , suggesting involvement of T-cellmediated autoimmune recognition of joint-specific antigens. Known proteins within joints that can be considered jointspecific are those found in articular cartilage. These include collagens of type II (CII), type IX (CIX), and type XI (CXI), and noncollagenous proteins such as aggrecan and COMP (3) (4) (5) . Some of these cartilage-specific proteins (CII, CXI, and aggrecan) have been shown to induce autoimmune arthritis in animals (6) (7) (8) . The most widely used model is collageninduced arthritis (CIA), induced with CII, the major protein component of cartilage. Immunization with CII leads to development of CIA in rats, mice, and apes (6, 9, 10) . In mice, the disease has a higher incidence and severity after immunization with heterologous CII compared with after immunization with autologous CII (11) . The immune recognition of CII, and the subsequent arthritis development, is surprisingly precise. The disease is associated with the expression of the MHC class II Aq molecule (12) . One limited region of CII, between positions 256 and 270, is recognized after immunization with rat CII (13) . This peptide is present in heterologous but not in mouse CII and can be recognized both in its posttranslational modified form (disaccharides bound to hydroxylysines) and in its nonmodified form (14) . The (13) . Still, autoreactive peptidespecific T cells can be activated, but only after immunization with mouse CII-(256-270).
In recent years there has been considerable progress in the understanding of the basic mechanisms for development of immune tolerance to self-antigens. Elimination of self-reactive T cells in thymus (central tolerance) has been clearly demonstrated (15) and autoreactive T cells which are not eliminated in the thymus may be eliminated or develop tolerance if exposed to autoantigens in the periphery (16, 17) . However, in other cases T cells respond to exposed autoantigens (18) . For the study of tolerance in autoimmune disease the nature of the antigen and the context by which it is presented is of critical importance. Thus, it is essential that disease-related autoantigens are studied. The expression of the CII gene is tightly controlled in a tissue-specific fashion through regulatory elements located in the promoter and first intron (19, 20) . We have hypothesized that T cells specific for CII in cartilage are not eliminated but are anergized and may play an important role in the development of CIA (11) . To (21) . This clone has earlier been shown to direct cartilage-specific expression in transgenic mice (22) . By site-directed mutagenesis, we introduced one nucleotide mutation leading to an amino acid shift from Asp to Glu (Fig. 1A) (Fig. 1B) . The 26.6-kb construct has been successfully expressed in 3T3 fibroblasts and the product has been shown to stimulate CII-specific T-cell hybridomas (14) . This construct was similarly used for microinjection of fertilized C3H.Q eggs. Two founders were generated: TSC-1 and TSC-2 (TSC, T-cell epitope in systemic collagen).
Screening and Transgenic Expression. Genomic DNA was prepared from the tip of the tail or a toe (23) . MMC Reverse Transcriptase (RT)-PCR. Tissue was frozen in liquid nitrogen and kept at -85°C until total RNA was prepared (24). Transgene-specific primers were used in the cDNA reactions, which were followed by PCR and agarose gel electrophoresis.
Collagen Preparations. Rat CII was extracted from the Swarm chondrosarcoma (25) after pepsin digestion or from lathyritic chondrosarcoma (26) and further purified as described (27) . The collagen was dissolved and stored in 0.1 M acetic acid until used. Collagen was also extracted by pepsin digestion from skin and the xiphoid process of transgenic mice and their nontransgenic littermates by the same method but without further purification. CII-(256-270) was synthesized as described (13 (28) and clinical scoring was performed as described (11 (Fig. 1A) .
To express the CII-(256-270) epitope in systemically occurring CI, a mouse Collal genomic clone containing all the regulatory elements for tissue-specific expression of CI, was mutated (Fig. lB) . The replacement mutations of 9 amino acid residues remained restricted to the X and Y positions of the collagen-specific Gly-X-Y sequence, thus leaving the glycine residues in every third position unchanged as a critical structural requirement for triple helicity of the native chimeric collagen.
The (Fig. 2 ), in accordance with the strict tissue-specific expression of the CII gene (19, 20) , although illegitimate CII mRNA has been observed in many organs from normal mice by using RT-PCR under conditions apparently better than those presently used (30, 33 (Fig. 5) . (27) , which has a cryptic CII-(256-270) peptide (13) (Fig.  4) . In addition, mice immunized with rat CII developed normal levels of anti-CII B-cell response as quantitated with the immunoglobulin ELISPOT assay (Fig. 5) Immunization with rat CII induced in all groups of nontransgenic littermates (C3H.Q) a high incidence of severe arthritis (Fig. 6) . None of the TSC-1 mice developed arthritis. MMC-1 (38) . Another possibility is that the mutated CII is not properly posttranslationally modified, which is important because glycosylated CII is more arthritogenic than the nonglycosylated CII (14) . However (12) , has striking similarities (11, 44) with the DR4 class II molecules in humans thought to be associated with RA (2) . Moreover, B cells producing antibodies to CII are frequently found in the joints of RA patients, and their occurrence has been shown to be associated with DR4 (39) (40) (41) . In contrast, in spite of considerable efforts by many investigators, only very few examples of CII-reactive human T cell clones have been reported (42, 43) . A (1996) 
